FAQ

P15-Tat

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2011
01220082011

Related topics

Related topics

1 relation
CIGB-300

Related mentions per year

Related mentions per year

2008-2018
20002005201020152020
P15-Tat
CIGB-300

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
CIGB-300, a proapoptotic peptide, inhibits angiogenesis in vitro and in vivo.
We have previously demonstrated that a proapoptotic cyclic peptide CIGB-300, formerly known as P15-Tat delivered into the cells… (More)
Is this relevant?
2009
2009
Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity.
CIGB-300, formerly known as P15-tat, is a proapoptotic peptide with established antiproliferative activity in vitro and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice.
The antitumor efficacy of the CK2 inhibitors so far described has not been extensively evaluated in cancer animal models. We have… (More)
Is this relevant?
2008
2008
CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo
Protein Kinase CK2 is a serine-threonine kinase frequently deregulated in many human tumors. Here, we hypothesized that a peptide… (More)
  • figure 2
  • figure 1
  • table 1
  • figure 3
Is this relevant?